Information Provided By: 
Fly News Breaks for January 4, 2017
HOLX
Jan 4, 2017 | 08:27 EDT
As previously reported, Evercore ISI downgraded Hologic to Hold from Buy and raised its price target to $42 from $41. Analyst Vijay Kumar said the recent Blood divestiture is a long-term positive but limits near-term earnings growth and is expected to be 34c dilutive to earnings. The analyst now expects a slight decline in earnings for FY17 before reverting back to double-digit growth in FY18.
News For HOLX From the Last 2 Days
There are no results for your query HOLX
